- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00937391
Contrast-enhanced MRI in Children 2 Months to <2 Years
October 19, 2015 updated by: Bayer
Open-label, Multi-center, Two-stage, Age Stratified, Pharmacokinetic, Safety, and Efficacy Study in Children 2 Months to < 2 Years of Age Undergoing Magnevist Injection Enhanced MRI
The purpose of this study is to determine pharmacokinetics, safety and efficacy of Magnevist in children 2 months to < 2 years of age
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Safety issues are addressed in the AE section
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01307
-
-
Sachsen-Anhalt
-
Halle, Sachsen-Anhalt, Germany, 06120
-
-
Schleswig-Holstein
-
Kiel, Schleswig-Holstein, Germany, 24105
-
-
Thüringen
-
Jena, Thüringen, Germany, 07740
-
-
-
-
California
-
San Diego, California, United States, 92123
-
-
Colorado
-
Aurora, Colorado, United States, 80045
-
-
Illinois
-
Chicago, Illinois, United States, 60614
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
-
-
Missouri
-
Kansas City, Missouri, United States, 64108-9898
-
St. Louis, Missouri, United States, 63110
-
-
Ohio
-
Akron, Ohio, United States, 44308
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033
-
-
Texas
-
Houston, Texas, United States, 77030
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 months to 1 year (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 2 months to < 2 years (23 months)
- Participants (male/female) who are scheduled to undergo gadolinium-enhanced MRI
- Able to comply with the study procedures
Exclusion Criteria:
- Clinical unstable participants (eg, intensive care unit)
- Renal Insufficiency
- Participants undergoing chemotherapy </= 48 hours prior to and up to 24 hours after the administration of Magnevist.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gadopentetate dimeglumine (Magnevist, BAY86-6661)
For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist.
Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW).
For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
|
For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist.
Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW).
For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Diagnostic Adequacy - Open-label Clinical Investigators (Per Protocol Set)
Time Frame: Within 5 minutes after injection
|
A clinical judgment by the open-label Clinical Investigators (CIs) as to whether ("yes") or not ("no") the CI could make a diagnosis from the image.
|
Within 5 minutes after injection
|
Dose Determined by Blinded Readers to be Superior for Diagnosis
Time Frame: Within 5 minutes after injection
|
Dose superiority was a calculation based upon the Blinder Readers' assessment of 4 visualization parameters
|
Within 5 minutes after injection
|
Paired-dose Comparison of Number of Participants With Dose Superiority Determined for 4 Lesion Visualization Variables - Blinded Readers
Time Frame: Within 5 minutes after injection
|
For each participant, the Blinded Reader indicated which dose had better contrast enhancement, better border delineation, clearer internal morphology, and provided more diagnostic information.
The dose chosen for 3 or 4 of these variables was the selected dose for that Reader and participant.
If each dose was superior on 2 variables, the dose which provided more diagnostic information was selected for that participant.
The dose selected for the majority of participants was the dose selected by that Reader; if chosen by 2 or 3 Readers, it was the selected dose.
|
Within 5 minutes after injection
|
PK Analysis - Total Clearance (CL)
Time Frame: 20 to 45 min and 4 to 8 hours post injection
|
Total clearance is the fraction of the volume of distribution (Vd) which is completely purified per unit of time and depends also on the plasma half-life of the drug.
|
20 to 45 min and 4 to 8 hours post injection
|
PK Analysis - Total Clearance (CL)/Body Weight (BW)
Time Frame: 20 to 45 min and 4 to 8 hours post injection
|
CL/BW = total clearance normalized by BW
|
20 to 45 min and 4 to 8 hours post injection
|
PK Analysis - Volume of Distribution at Steady State (Vss)
Time Frame: 20 to 45 min and 4 to 8 hours post injection
|
Vss is an estimate of drug distribution independent of the elimination process and is proportional to the amount of drug in the body versus the drug plasma concentration at steady-state.
|
20 to 45 min and 4 to 8 hours post injection
|
PK Analysis - Volume of Distribution at Steady State (Vss) /Body Weight (BW)
Time Frame: 20 to 45 min and 4 to 8 hours post injection
|
Vss/BW = volume of distribution at steady state normalized by body weight
|
20 to 45 min and 4 to 8 hours post injection
|
PK Analysis - Area Under the Drug Concentration-time Curve (AUC)
Time Frame: Samples taken 20 to 45 min and 4 to 8 hours post injection. AUC calculated from time of injection to infinity.
|
AUC = Area under the drug concentration-time curve from administration to infinity
|
Samples taken 20 to 45 min and 4 to 8 hours post injection. AUC calculated from time of injection to infinity.
|
PK Analysis - t 1/2
Time Frame: Samples taken at 20 to 45 min and at 4 to 8 hours post injection; t 1/2 calculated from area under the drug concentration-time curve from administration to infinity
|
t 1/2 = termination elimination half-life calculated from the area under the drug concentration-time curve from administration to infinity
|
Samples taken at 20 to 45 min and at 4 to 8 hours post injection; t 1/2 calculated from area under the drug concentration-time curve from administration to infinity
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Number of Lesions Detected - Stage 1
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator; unenh.
image = unenhanced image; comb.
image= combined unenhanced and enhanced image.
The Blinded Readers and the open-label Clinical Investigators determined the number of participants with 0, 1, 2, and 3 or more lesions.
|
Within 5 minutes after injection
|
Number of Participants With Number of Lesions Detected - Stage 2
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator; unenh.
image = unenhanced image; comb.
image= combined unenhanced and enhanced image.
The Blinded Readers and the open-label Clinical Investigators determined the number of participants with 0, 1, 2, and 3 or more lesions.
|
Within 5 minutes after injection
|
Number of Participants With Quality of Lesion Visualization - Stage 1
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator.
The Blinded Readers and the open-label Clinical Investigators determined the quality of lesion visualization with the unenhanced and the combined image sets based on a 3-point scale (1=excellent - lesion clearly seen and diagnosis possible; 2=fair but adequate - most of lesion seen and diagnosis possible; and 3=poor - lesion barely seen and diagnosis not possible)
|
Within 5 minutes after injection
|
Number of Participants With Quality of Lesion Visualization - Stage 2
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator.
The Blinded Readers and the open-label Clinical Investigators determined the quality of lesion visualization with the unenhanced and the combined image sets based on a 3-point scale (1=excellent - lesion clearly seen and diagnosis possible; 2=fair but adequate - most of lesion seen and diagnosis possible; and 3=poor - lesion barely seen and diagnosis not possible)
|
Within 5 minutes after injection
|
Number of Participants With Quality of Border Delineation - Stage 1
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator.
The Blinded Readers and the open-label Clinical Investigators determined the quality of border delineation based on a 3-point scale (1=excellent - border completely delineated; 2=fair but adequate - some of the border is delineated; and 3=poor - entire or almost the entire border is not delineated) by image set
|
Within 5 minutes after injection
|
Number of Participants With Quality of Border Delineation - Stage 2
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator.
The Blinded Readers and the open-label Clinical Investigators determined the quality of border delineation based on a 3-point scale (1=excellent - border completely delineated; 2=fair but adequate - some of the border is delineated; and 3=poor - entire or almost the entire border is not delineated) by image set
|
Within 5 minutes after injection
|
Most Frequent Diagnostic Findings With Unenhanced Images - Stage 1
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator.
The Blinded Readers and the open-label Clinical Investigators determined the most frequent diagnostic findings with the unenhanced images
|
Within 5 minutes after injection
|
Most Frequent Diagnostic Findings With Unenhanced Images - Stage 2
Time Frame: Within 5 minutes after injection
|
BR = blinded reader; CI = clinical investigator.
The Blinded Readers and the open-label Clinical Investigators determined the most frequent diagnostic findings with the unenhanced images
|
Within 5 minutes after injection
|
Overall Number of Participants With Change in Diagnosis From Unenhanced to Combined Images - Stage 1
Time Frame: Within 5 minutes after injection
|
The Blinded Readers and the open-label Clinical Investigators determined the number of participants with a change in diagnosis from unenhanced to combined images.
BR = blinded reader; CI = clinical investigator
|
Within 5 minutes after injection
|
Overall Number of Participants With Change in Diagnosis From Unenhanced to Combined Images - Stage 2
Time Frame: Within 5 minutes after injection
|
The Blinded Readers and the open-label Clinical Investigators determined the number of participants with a change in diagnosis from unenhanced to combined images.
BR = blinded reader; CI = clinical investigator
|
Within 5 minutes after injection
|
Number of Participants With Specific Change in the Diagnosis From Unenhanced to Combined Images - Stage 1
Time Frame: Within 5 minutes after injection
|
Those participants for whom the diagnosis changed for at least 1 Blinded Reader from unenhanced to combined images are presented for Stage 1.
For completeness, the corresponding data for these participants are presented for the open-label Clinical Investigators.
BR=Blinded Reader; CI=Clinical Investigator.
|
Within 5 minutes after injection
|
Number of Participants With Specific Change in the Diagnosis From Unenhanced to Combined Images - Stage 2
Time Frame: Within 5 minutes after injection
|
Those participants for whom the diagnosis changed for at least 1 Blinded Reader from unenhanced to combined images are presented for Stage 2. For completeness, the corresponding data for these participants are presented for the open-label Clinical Investigators.
BR=Blinded Reader; CI=Clinical Investigator
|
Within 5 minutes after injection
|
Number of Participants With Diagnostic Confidence - Stage 1
Time Frame: Within 5 minutes after injection
|
The overall diagnostic confidence of the Blinded Readers and the open-label Clinical Investigators was indicated on a 3-point scale: 1=not confident; 2=confident; and 3=very confident.
BR=Blinder Reader; CI=Clinical Investigator
|
Within 5 minutes after injection
|
Number of Participants With Diagnostic Confidence - Stage 2
Time Frame: Within 5 minutes after injection
|
The overall diagnostic confidence of the Blinded Readers and the open-label Clinical Investigators was indicated on a 3-point scale: 1=not confident; 2=confident; and 3=very confident.
BR=Blinder Reader; CI=Clinical Investigator
|
Within 5 minutes after injection
|
Management Based on Unenhanced Images - Stage 1
Time Frame: Within 5 minutes before injection
|
For Stage 1 based on unenhanced images, the recommended management is presented as determined by the open-label Clinical Investigators.
|
Within 5 minutes before injection
|
Management Based on Unenhanced Images - Stage 2
Time Frame: Within 5 minutes before injection
|
For Stage 2 based on unenhanced images, the recommended management is presented as determined by the open-label Clinical Investigators.
|
Within 5 minutes before injection
|
Overall Number of Participants With Change in Management From Unenhanced to Combined Images - Stage 1
Time Frame: Within 5 minutes after injection
|
For Stage 1, the number of participants for whom the recommended management of the open-label Clinical Investigators changed from unenhanced to combined images is presented for both doses.
|
Within 5 minutes after injection
|
Overall Number of Participants With Change in Management From Unenhanced to Combined Images - Stage 2
Time Frame: Within 5 minutes after injection
|
For Stage 2, the number of participants for whom the recommended management of the open-label Clinical Investigators changed from unenhanced to combined images is presented for the optimal efficacious dose determined in Stage 1.
|
Within 5 minutes after injection
|
Number of Participants With Specific Change in Management From Unenhanced to Combined Images - Stage 1
Time Frame: Within 5 minutes after injection
|
The actual change in management from unenhanced to combined images recommended by the open-label Clinical Investigators is presented for both doses in Stage 1
|
Within 5 minutes after injection
|
Number of Participants With Specific Change in Management From Unenhanced to Combined Images - Stage 2
Time Frame: Within 5 minutes after injection
|
The actual change in management from unenhanced to combined images recommended by the open-label Clinical Investigators is presented in Stage 2 for the optimal efficacious dose determined in Stage 1
|
Within 5 minutes after injection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
July 10, 2009
First Submitted That Met QC Criteria
July 10, 2009
First Posted (Estimate)
July 13, 2009
Study Record Updates
Last Update Posted (Estimate)
November 18, 2015
Last Update Submitted That Met QC Criteria
October 19, 2015
Last Verified
October 1, 2015
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 91784
- 2009-013081-17 (EudraCT Number)
- 312046 (Other Identifier: company internal)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Magnetic Resonance Imaging
-
BayerCompletedMagnetic Resonance Imaging | Magnetic Resonance AngiographyPoland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
-
Chinese University of Hong KongRecruitingMagnetic Resonance ImagingHong Kong
-
Institut National de la Santé Et de la Recherche...Not yet recruitingMagnetic Resonance Imaging
-
Mayo ClinicCompletedMagnetic Resonance ImagingUnited States
-
University Hospital, GrenobleCompletedMagnetic Resonance ImagingFrance
-
Children's Hospital Medical Center, CincinnatiCompleted
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance ImagingFrance
-
Centre Hospitalier Universitaire, AmiensCompletedMagnetic Resonance Imaging
-
Nihon UniversityCompleted
-
GuerbetCompletedMagnetic Resonance ImagingFrance, Austria, Hungary, Poland
Clinical Trials on Gadopentetate dimeglumine (Magnevist, BAY86-6661)
-
BayerCompleted
-
BayerCompletedMyocardial InfarctionUnited States, Argentina
-
BayerCompletedFibrosis | Renal Insufficiency | Kidney FailureUnited States
-
BayerCompletedMagnetic Resonance ImagingChina, Korea, Republic of, Japan
-
BayerCompletedPeripheral Vascular Diseases | Peripheral Arterial Diseases | Magnetic Resonance AngiographyJapan
-
Bracco Diagnostics, IncCompletedCarotid, Aortic, Renal or Peripheral Artery DiseaseChina
-
BayerCompleted
-
BayerCompleted